Pharvaris (NASDAQ:PHVS) Reaches New 12-Month High - Should You Buy?

Key Points

• Pharvaris shares reached a new 52-week high of $29.89, the stock has a market cap of about $1.87B, and analysts show a generally bullish view with an average price target of $42.73 (11 Buys, 2 Holds, 1 Sell) and individual targets as high as $60.
• The company reported an earnings miss for the quarter (EPS -$0.84 vs. -$0.69 expected), carries a negative PE (-8.48), and remains a clinical-stage biotech developing oral plasma kallikrein inhibitor PHA121 for hereditary angioedema, highlighting development and profitability risks.
• CEO Berndt Modig sold 23,333 shares under a pre-arranged Rule 10b5-1 plan (a ~14.1% reduction in his holdings), while institutional investors such as General Atlantic and Wellington hold significant stakes.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The company traded as high as $29.89 and last traded at $29.6450, with a volume of 45241 shares traded. The stock had previously closed at $28.78.

Analysts Set New Price Targets

A number of research firms have recently issued reports on PHVS. Weiss Ratings reissued a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, January 22nd. Wedbush upped their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 7th. Citigroup restated a "buy" rating on shares of Pharvaris in a research note on Wednesday. HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an "outperform" rating for the company in a research note on Monday, April 6th. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $42.73.

Pharvaris Stock Performance

The stock has a market capitalization of $1.87 billion, a PE ratio of -8.48 and a beta of -2.58. The business has a 50 day moving average of $27.20 and a two-hundred day moving average of $25.63.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings data on Friday, April 3rd. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.15). On average, equities analysts expect that Pharvaris N.V. will post -2.71 EPS for the current fiscal year.

Insider Buying and Selling

In other Pharvaris news, CEO Berndt Modig sold 23,333 shares of the stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $27.74, for a total value of $647,257.42. Following the completion of the sale, the chief executive officer directly owned 142,084 shares in the company, valued at approximately $3,941,410.16. This trade represents a 14.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 11.84% of the company's stock.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Wellington Management Group LLP purchased a new stake in Pharvaris in the third quarter valued at about $43,282,000. Paradigm Biocapital Advisors LP raised its stake in Pharvaris by 72.7% in the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock valued at $45,796,000 after buying an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. purchased a new stake in Pharvaris in the third quarter valued at about $15,613,000. Commodore Capital LP raised its stake in Pharvaris by 26.5% in the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company's stock valued at $60,341,000 after buying an additional 507,043 shares during the last quarter. Finally, General Atlantic L.P. raised its stake in Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company's stock valued at $200,380,000 after buying an additional 500,000 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.